BlossomHill presents preclinical data on BH-501284 pan-KRAS inhibitor
BlossomHill Therapeutics reports Q2 results
BlossomHill Therapeutics lead drug data lifts outlook at H.C. Wainwright
BlossomHill Therapeutics shares rise 4.4% on BH-30643 trial update
BlossomHill Therapeutics Presents Updated Data from Ongoing Phase 1/2 SOLARA Trial Demonstrating Encouraging Anti-Tumor Activity of OMNI-EGFR™ Inhibitor BH-30643 in EGFR C797S-Positive NSCLC at IASLC 2026 World Conference on Lung Cancer